How do GLP-1 agonists enhance glycemic control in diabetes management?

GLP-1 agonists enhance glycemic control primarily through increasing glucose-dependent insulin secretion. These agents mimic the action of the incretin hormone GLP-1 (glucagon-like peptide-1), which is naturally produced in the gut. When glucose levels rise after a meal, GLP-1 agonists stimulate the pancreatic beta cells to release more insulin, but this effect is glucose-dependent, meaning that they predominantly promote insulin secretion when blood glucose levels are elevated. This mechanism helps to lower blood glucose levels post-prandially (after meals) while minimizing the risk of hypoglycemia, a common concern with other types of insulin treatments.

Additionally, GLP-1 agonists also provide other benefits in diabetes management, such as slowing gastric emptying and reducing appetite, which can contribute to weight loss. However, their primary mode of action in improving glycemic control is through enhancing insulin secretion in a glucose-dependent manner, thus making option B the correct choice.